A-103 is under clinical development by TCR Cure Biopharma Technology and currently in Phase I for Lung Cancer. According to GlobalData, Phase I drugs for Lung Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how A-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
A-103 overview
TC-A103 is under development for the treatment of relapsed or refractory solid tumors including ovarian cancer, cervical cancer, endometrial cancer, lung cancer, testicular tumor, other solid tumors. The therapeutic candidate is administered through parenteral route. It comprises of T-cells genetically engineered to express chimeric antigen receptors (CAR) targeting cells expressing an undisclosed tumor associated antigen. It is being developed based on ASPIRE technology platform.
TCR Cure Biopharma Technology overview
TCR Cure Biopharma Technology (Tiankeya), a cutting-edge company in the field of immune cell therapy. The company is headquartered in China.
For a complete picture of A-103’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
